ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 309

Clinical Significance of Cytokine Profile with Interleukin-18 and -6 in Systemic Juvenile Idiopathic Arthritis

Masaki Shimizu, Natsumi Inoue, Yuko Tasaki, Sayaka Ishikawa, Kazuyuki Ueno and Akihiro Yachie, Department of Pediatrics, School of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, Kanazawa, Japan

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Systemic JIA and interleukins (IL)

  • Tweet
  • Email
  • Print
Session Information

Title: Pediatric Rheumatology - Pathogenesis and Genetics

Session Type: Abstract Submissions (ACR)

Background/Purpose

 Innate proinflammatory cytokines interleukin (IL)-6 and IL-18 are critical for perpetuating the inflammatory processes in systemic juvenile idiopathic arthritis (s-JIA) and macrophage activation syndrome (MAS). To assess the role of IL-6 and IL-18 in the pathogenesis of s-JIA and MAS, and to investigate the clinical significance of serum cytokine profile with IL-6 and IL-18 in s-JIA and MAS, we analyzed the serum IL-6 and IL-18 in patients with s-JIA and compared them with the clinical features of s-JIA.

Methods

 71 patients with s-JIA including 23 patients with MAS were analyzed. Levels of IL-6 and IL-18 were quantified in serum by enzyme-linked immunosorbent assay. Results were compared with clinical features of s-JIA.

Results 

 Two distinct s-JIA patient subsets based on their serum IL-6 and IL-18 levels were identified: an IL-18 dominant (IL-18/IL-6>1000) and an IL-6 dominant (IL-18/IL-6<1000). The IL-6 dominant subset had a significantly greater number of joints with active disease and higher serum levels of matrix metalloproteinase-3, whereas the IL-18-dominant subset was more likely to develop MAS. The cut off value of serum IL-18 to predict the development of MAS was 52500pg/ml with 91.3% of sensitivity and 81.3% of specificity. The patients with IL-18 dominant pattern were likely to have monophasic or polycyclic disease course, whereas the patients with IL-6 dominant pattern were likely to have persistent disease course. Serum IL-18 levels in patients achieved remission decreased to the levels <1,000 pg/mL in inactive phase and normalized in remission phase. In contrast, serum IL-18 levels in patients experienced relapse during withdrawal of steroid within 12 months after disease onset demonstrated a sustained elevation of serum IL-18 levels (>1,000 pg/mL) during the inactive phase.

Conclusion

 Two subsets of patients with s-JIA, one which is prone for arthritis and another with prone for MAS, can be identified on the basis of their serum IL-6 and IL-18 levels. These two subsets appear to be characterized by certain distinct clinical features. Monitoring the cytokine profile with IL-18 and IL-6 might be useful to predict disease course. Furthermore, serum IL-18 levels reflect the biological activities of the immune system in s-JIA and may predict the development of MAS and the prognosis of s-JIA.


Disclosure:

M. Shimizu,
None;

N. Inoue,
None;

Y. Tasaki,
None;

S. Ishikawa,
None;

K. Ueno,
None;

A. Yachie,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-significance-of-cytokine-profile-with-interleukin-18-and-6-in-systemic-juvenile-idiopathic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology